Publication: 2335

N0436 (Alliance): A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane-containing therapy
      QxMD      Google Scholar   
Citation:
Clin Breast Cancer vol 16 (1) 23-30
Year:
2016
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
This research was also supported in part by funds from Bristol-Myers Squibb and Imclone systems.
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
5
Parents:
734  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, CA-37404, 1U10CA180799, U10 CA060276, U10 CA037404, U10 CA180821, U10 CA063848, CA-25224, CA-60276, 1U10CA180790, U10 CA180790, P30 CA015083, CA-63848, U10 CA180882, U10CA180821, U10 CA180799, U10 CA180867, U10 CA025224  
Corr. Author:
 
Authors:
               
Networks:
FL003, LAPS-MN026, PR028, WINCORP   
Study
NCCTG-N0436
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
breast cancer, metastatic, EGFR, cetuximab, irinotecan